333
Participants
Start Date
October 26, 2020
Primary Completion Date
October 4, 2021
Study Completion Date
October 4, 2021
Albuterol eMDPI DS
"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:~* Device 1: Albuterol eMDPI~* Device 2: Albuterol eMDPI Patient-facing smart device application (App)~* Device 3: DHP Cloud solution)~* Device 4: Provider-facing dashboard (dashboard)"
albuterol
Standard of care albuterol-administering rescue inhaler
Teva Investigational Site 14221, New York
Teva Investigational Site 14208, Pittsburgh
Teva Investigational Site 14210, Philadelphia
Teva Investigational Site 14234, Chapel Hill
Teva Investigational Site 14300, Charleston
Teva Investigational Site 14196, Greenville
Teva Investigational Site 14201, Gainesville
Teva Investigational Site 14195, Savannah
Teva Investigational Site 14304, Albany
Teva Investigational Site 14197, Aventura
Teva Investigational Site 14306, Miami
Teva Investigational Site 14215, Sarasota
Teva Investigational Site 14232, Birmingham
Teva Investigational Site 14305, Louisville
Teva Investigational Site 14191, Owensboro
Teva Investigational Site 14187, Cincinnati
Teva Investigational Site 14233, Ann Arbor
Teva Investigational Site 14190, Greenfield
Teva Investigational Site 14217, Evanston
Teva Investigational Site 14218, Springfield
Teva Investigational Site 14188, San Antonio
Teva Investigational Site 14192, San Antonio
Teva Investigational Site 14189, San Antonio
Teva Investigational Site 14198, Denver
Teva Investigational Site 14236, Colorado Springs
Teva Investigational Site 14302, Los Angeles
Teva Investigational Site 14301, Stockton
Teva Investigational Site 14220, New Haven
Teva Investigational Site 14207, Bellevue
Teva Investigational Site 14200, Providence
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY